Cosmetic treatment, preferably straightening and smoothing of human keratin fibers e.g. hair, comprises applying agent to modulate expression, structure and/or activity of e.g. keratin associated protein7-1 and (ii) protein on fibers

摘要

Cosmetic treatment of keratin fibers of a mammal to alter its shape, comprises applying, on the keratin fibers, (i) at least one agent for modulating expression, structure and/or activity of at least one gene and/or protein consisting of e.g. keratin associated protein (KRTAP)7-1 or one agent for modulating expression, structure and/or activity of at least one gene and/or protein consisting of e.g. interfering RNA and (ii) at least one protein consisting of e.g. KRTAP7-1. Cosmetic treatment of keratin fibers of a mammal to alter its shape, comprises applying, on the keratin fibers, (i) at least one agent for modulating expression, structure and/or activity of at least one gene and/or protein consisting of keratin associated protein (KRTAP)7-1, KRTAP8-1, KRTAP13-1, KRTAP19-1, KARTAP19-3, actin alpha -2 (ACTA2), calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1), CORIN, endothelin receptor type A (EDNRA), EF-hand domain-containing protein 1 (EFHD1), fatty acid binding protein 4 (FABP4), guanine nucleotide-binding protein-like 3 (GNL3L), GPRC5D, KRBA2, lectin, galactoside-binding, soluble, 3 (LGALS3), LOC339047, NEFL, selenium-binding protein 1 (SELENBP1), SLC05A1, SMA4, TAGLN, zinc finger protein 652 (ZNF652), FKBP1A, pregnancy-associated plasma protein A (PAPPA), retinoic acid receptor responder 1 (RARRES1), SLC35E2, SOX 6 and STON2 or one agent for modulating expression, structure and/or activity of at least one gene and/or protein consisting of interfering RNA, antisense oligonucleotide, monoclonal or polyclonal antibody, aptamer, bosentan, cigfitazone, fasudil, isoproterenol, PD98059, resveratrol, 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol -2-yl]-3-butyn-1-ol (RWJ 67657), troglitazone, alpha-1, 25-dihydroxy vitamin D3, 15-S-hydroxyeicosatetraenoic acid, batimastat, bisindolylmaleimide, dehydroisoandrosterone, indinavir, lipoate, lysophosphatidic acid, N-Ac-Leu-Leu-norleucinal, nelfinavir, octanoic acid, prostaglandin, F2 alpha, ritonavir, 3-1-3-(amidinothio)propyl-1H-indol-3-(1-methyl-1H-indol-3-yl) maleimide (RO31-8220), roscovitine, saquinavir, selenomethylselehocysteine, 1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), galectin-3 antagonist (GCS-100), beta-estradiol, Chrdmium, raloxifene, amiodarone, amitriptyline, chlorpromazine, fluoxetine, imipramine, tamoxifen, thioridazine, decitabine, retinoic acid, 2-methoxyestradiol and its salts and esters, 5-fluorouracil, fulvestrant, actinomycin D, Y27632, 15-deoxy-delta-12,14-prostaglandin J 2, heparin, 2-morpholin-4-yl-8-phenylchromen-4-one (LY294002), sirolimus, tyrphostin AG 1295, wortmannin, cyclosporin A, deflazacort, dexamethasone, phenylephrine, prednisolone, 9-cis-retinoic acid, aldosterone, bexarotene, butyric acid, indomethacin, L-triiodothyronine, pioglitazone, cholesterol, and/or eflornithine and their salts and esters and (ii) at least one protein consisting of (KRTAP)7-1, KRTAP8-1, KRTAP13-1, KRTAP19-1, KARTAP19-3, actin alpha -2 (ACTA2), calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1), CORIN, endothelin receptor type A (EDNRA), EF-hand domain-containing protein 1 (EFHD1), fatty acid binding protein 4 (FABP4), guanine nucleotide-binding protein-like 3 (GNL3L), GPRC5D, KRBA2, lectin, galactoside-binding, soluble, 3 (LGALS3), LOC339047, NEFL, Selenium-binding protein 1 (SELENBP1), SLC05A1, SMA4, TAGLN, zinc finger protein 652 (ZNF652), FKBP1A, pregnancy-associated plasma protein A (PAPPA), retinoic acid receptor responder 1 (RARRES1), SLC35E2, SOX 6 and STON2. An independent claim is included for screening straighteners and/or smoothing assets comprising introducing hair follicles in culture in the presence or absence of a candidate compound, measuring the expression of gene or protein, identifying the candidate compound as: curling assests if the expression of at least one gene or protein consisting of KRTAP7-1, KRTAP8-1, KRTAP13-1, KRTAP19-1, KARTAP19-3, ACTA2, CAMK2N1, CORIN, EDNRA, EFHD1, FABP4, GNL3L, GPRC5D, KRBA2, LGALS3, LOC339047, NEFL, SELENBP1, SLC05A1, SMA4, TAGLN and ZNF652 is increased in the presence of the candidate compound compared to the expression measured in the absence of the candidate compound or if the expression of at least one gene or protein consisting of FKBP1A, PAPPA, RARRES1, SLC35E2, SOX 6 and STON2 is decreased in the presence of the candidate compound compared to the expression measured in the absence of the candidate compound; and as relaxer and/or smoothing assests if the expression of at least one gene or protein consisting of FKBP1A, PAPPA, RARRES1, SLC35E2, SOX 6 and STON2 is increased in the presence of the candidate compound compared to the expression measured in the absence of the candidate compound or if the expression of at least one gene or protein consisting of KRTAP7-1, KRTAP8-1, KRTAP13-1, KRTAP19-1, KARTAP19-3, ACTA2, CAMK2N1, CORIN, EDNRA, EFHD1, FABP4, GNL3L, GPRC5D, KRBA2, LGALS3, LOC339047, NEFL, SELENBP1, SLC05A1, SMA4, TAGLN and ZNF652 is decreased in the presence of the candidate compound compared to the expression measured in the absence of the candidate compound.